Several other analysts have also recently weighed in on the stock. Bank of America started coverage on shares of Zai Lab in a research report on Friday, July 12th. They set a buy rating and a $43.00 price objective on the stock. ValuEngine cut shares of Zai Lab from a buy rating to a hold rating in a research report on Thursday, August 1st. Zacks Investment Research cut shares of Zai Lab from a buy rating to a hold rating in a research report on Saturday, June 15th. Macquarie started coverage on shares of Zai Lab in a research report on Friday, July 5th. They set an outperform rating and a $36.54 price objective on the stock. Finally, Leerink Swann set a $47.00 price objective on shares of Zai Lab and gave the company a buy rating in a research report on Monday, July 15th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Zai Lab presently has a consensus rating of Buy and a consensus target price of $38.25.
Zai Lab stock opened at $31.12 on Friday. The firm’s fifty day moving average is $34.76. The stock has a market cap of $1.81 billion, a PE ratio of -11.79 and a beta of 1.36. Zai Lab has a fifty-two week low of $14.29 and a fifty-two week high of $36.78.
About Zai Lab
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
See Also: Cost of Goods Sold (COGS)
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.